1. Discounting health effects in pharmacoeconomic evaluations

   • J. M. Bos
   • Maarten J. Postma
   • Lieven Annemans

   Current Opinion 17 September 2012 Pages: 639 - 649

   

2. Price differentiation and transparency in the global pharmaceutical marketplace

   • David B. Ridley

   Current Opinion 17 September 2012 Pages: 651 - 658

   

3. Evaluating health-related quality-of-life studies in paediatric populations

   • Mirella De Civita
   • Dean Regier
   • Carlo A. Marra

   Review Article 17 September 2012 Pages: 659 - 685

   

4. The state of patient-reported outcomes in atrial fibrillation

   • Karin Coyne
   • Mary Kay Margolis
   • Peter Zimetbaum

   Review Article 17 September 2012 Pages: 687 - 708

   

5. Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information?

   • Kun-Sei Lee
   • Werner B. F. Brouwer
   • Hye-Won Koo

   Review Article 17 September 2012 Pages: 709 - 721

   

6. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

   • Bernd Brüggenjürgen
   • Dagmar Selim
   • Stefan N. Willich

   Original Research Article 17 September 2012 Pages: 723 - 731

   

7. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease

   • Kristen Migliaccio-Walle
   • J. Jaime Caro
   • Judith A. O’Brien

   Original Research Article 17 September 2012 Pages: 733 - 742

   

8. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

   • Eduardo Carracedo-Martínez

   Correspondence 17 September 2012 Pages: 743 - 743

9. The authors’ reply

   • Andrew Moore
   • Ceri Phillips
   • Simone Crespi

   Correspondence 17 September 2012 Pages: 743 - 744